The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma

Kryachok, Iryna; Martynchyk, A.; Filonenko, K.; Grabovoy, A. N.; Antoniuk, S.A.; Tytorenko, I.; Novosad, O.; Kadnikova, T.; Aleksik, Olena; Stepanishyna, I.

doi:10.1093/annonc/mdw375.18

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although MUM1 protein was co-expressed with CD10+ in the brain tissue of our 8 GCB patients (CD10+/Bcl6+/MUM1+), the survival benefit was still seen, which has never been observed previously. Currently, the outcome of CD10+/MUM1+ in systemic DLBCL patients are not yet known [4, 22–24]. Furthermore, the Bcl6+ non-GCB tends to have a better RFS and OS than the Bcl6- counterpart.…”

Section: Discussionmentioning

confidence: 99%

Treatment outcome and prognostic factors in PCNSL

et al. 2019

View full text Add to dashboard Cite

Objectives Standard treatment with a thiotepa-based regimen in countries with a limited resource is less feasible. Aims of the study were to evaluate the treatment outcome, and identify the prognostic factors in patients with primary central nervous system lymphoma (PCNSL). Methods We conducted a retrospective study of 43 patients diagnosed with PCNSL, DLBCL subtype, who were treated with either HDMTX-based regimen, whole brain radiotherapy (WBRT), or both between 2010 and 2017. Results There were 43 patients with a median age of 65 years (range 34–89 years). Protein expression of CD10, Bcl6, MUM1, Bcl2 and MYC were found in 19, 86, 91, 91 and 23%, respectively. Both germinal center B cell (GCB) and double-expressor (MYC+/Bcl2+) lymphomas were found in 21%. Multiple brain lesions and maximum tumor diameter (MTD) ≥5 cm were seen in 27 and 10 patients, respectively. Chemotherapy combined with WBRT, chemotherapy and WBRT were given to 20, 14 and 9 patients, respectively. Overall complete remission (CR) rate was 55.8%. Those receiving a combined-modality therapy had a higher CR rate than those treated with either chemotherapy (75% versus 36%, p = 0.036) or WBRT (75% versus 44%, p = 0.109). Median follow-up time was 17 months, and a 7-year overall survival (OS) was 40%. Features associated with a prolonged OS were an ECOG score ≤ 2 ( p = 0.001), multiple brain lesions ( p = 0.010), multiple area of brain involvement ( p = 0.023), MTD < 5 cm ( p = 0.004), GCB subtype ( p = 0.003) and positive CD10 staining ( p = 0.007). Expression of Bcl2 protein was associated with a significantly worse OS in the non-GCB DLBCL patients. Discussion The factors affecting treatment outcomes in PCNSL were cell of origin of DLBCL, lesion characteristics, patients’ status and treatment regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment outcome and prognostic factors in PCNSL

et al. 2019

View full text Add to dashboard Cite

show abstract

“…And some study results demonstrated positive prognosis in case of positive expression of this marker [6,7].…”

Section: Introductionmentioning

confidence: 95%

Prognostic Value of Immunohistochemical Markers in Patients With Diffuse Large B-Cell Lymphoma

Martynchyk¹,

Гуріанов

Kriachok³

2018

EUREKA: Health Sciences

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is a potentially curable disease, but standard treatment is not effective enough for all patients. That is why so important to identify high risk patients who need more aggressive therapy at the time of diagnosis. Nowadays prognosis for patients with DLBCL is based on International prognostic index (IPI). However, this index consists of only clinical parameters and does not include the biological characteristics of the tumour. Immunohistochemistry (IHC) markers could also play a prognostic role. There are some publications regarding predictive and prognostic role of expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30, but their results are controversial. The aim of our study was to analyze prognostic role of these markers, to compare survival of patients with positive and negative expression of these markers and to build a prognostic model which include biological parameters for identifying high risk patients. There were statistically significant differences in EFS between the group of patients with negative and positive expression of CD10 (51.5 % versus 72.5 %, р=0.01) and in OS between the group of patients with negative and positive expression of Bcl-6 (61.1 % versus 79.6 %, р=0.03). Six-factors nonlinear neural network prediction model (MLP_6) was built. The sensitivity of the model is 63.2 % (95 % CІ 49.3 % – 75.6 %), specificity – 85.2 % (95 % CІ 79.1 % – 90.1 %). Prognostic factors include negative IHC expression of Bcl-6, CD10, non-GCB molecular subtype (according to algorithm Hans), gender (male), advanced Ann-Arbor stages, >2extranodal involvement. Our nonlinear neural network prediction model could improve prognostic role of IPI by adding of biological tumour characteristics (IHC expression of CD10, Bcl-6, molecular subtype by IHC algorithm).

show abstract

The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma

Cited by 2 publications

References 0 publications

Treatment outcome and prognostic factors in PCNSL

Treatment outcome and prognostic factors in PCNSL

Prognostic Value of Immunohistochemical Markers in Patients With Diffuse Large B-Cell Lymphoma

Contact Info

Product

Resources

About